Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: J Pain. 2019 Jun 12;21(1-2):146–160. doi: 10.1016/j.jpain.2019.05.017

Table 2: Summary of In Vivo Potency and Tolerance Values for SRI-22141.

Potency (A50) and tolerance (days to zero efficacy) values calculated from Figures 2–4. Values reported with 95% CI.

Pain Model Acute A50 mg/kg (95% CI) Tolerance – Days to Zero Efficacy (95% CI)
SRI-22141
0.32 mg/kg		 SRI-22141
1 mg/kg		 SRI-22141
3.2 mg/kg		 SRI-22141
10 mg/kg		 Morphine
10 mg/kg
Tail Flick 0.95 (0.64–1.3) - - - - -
HIV Neuropathy 2.3 (1.7-3.0) - 2.1 (1.6-7.3) 3.0 (2.6-3.9) 4.9 (3.6-15.2)# 3.0 (2.7-3.6)
CIPN 0.83 (0.70-0.97) 2.1 (1.7-7.2) 2.3 (1.9-3.7) 4.3 (3.8-5.2)#& 5.2 (4.3-9.4)#& 2.2 (1.9-3.3)
#

Significantly different from morphine comparison (non-overlapping CI).

&

Significantly different from 1 mg/kg SRI-22141 in same pain type (non-overlapping CI).